Skip to main content
SpringerLink
Log in

Paricalcitol in the treatment of MHD with secondary hyperparathyroidism and bone pain

  • Nephrology - Letter to the Editor
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Availability of data

The data that support the findings of this study are available from the corresponding author, Santao Ou, upon reasonable request.

References

  1. KDIGO 2017 Clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl (2011) 7: 1–59, https://doi.org/10.1016/j.kisu.2017.04.001 (2017)

  2. Santao Ou LX (2022) A review of the diagnosis and research progress of renal bone disease. Med J West China 34:157–160+167

  3. Žilinská Z, Dedinská I, Breza J, Laca L (2017) Effect of paricalcitol on bone density after kidney transplantation: analysis of 2 transplant centers. Iran J Kidney Dis 11:461–466

    PubMed  Google Scholar 

  4. Yolbaş S et al (2018) Paricalcitol inhibits the Wnt/beta-catenin signaling pathway and ameliorates experimentally induced arthritis. Turk J Med Sci 48:1080–1086. https://doi.org/10.3906/sag-1804-62

    Article  CAS  PubMed  Google Scholar 

  5. Qu Y, Wu Y, Jiang H (2021) Research progress in the pharmacological actions of the multiple effects and selectivity of the vitamin D analogue paricalcitol: a narrative review. Ann Palliat Med 10: 11177–11190, https://doi.org/10.21037/apm-21-2249

  6. Yang L, Cai L, Ding H, Chen Y (20190 Application of (18)F-NaF PET/CT bone imaging in hyperparathyroidism bone disease. Int J Radiat Med Nucl Med 132–139

  7. Beheshti M et al (2015) (18)F-NaF PET/CT: EANM procedure guidelines for bone imaging. Eur J Nucl Med Mol Imaging 42:1767–1777. https://doi.org/10.1007/s00259-015-3138-y

    Article  CAS  PubMed  Google Scholar 

  8. Aaltonen L et al (2020) Correlation between (18)F-Sodium Fluoride positron emission tomography and bone histomorphometry in dialysis patients. Bone 134:115267. https://doi.org/10.1016/j.bone.2020.115267

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Jingyi Chen, Liang Cai, Xiangqiong Wen, Xin Xie, and Santao Ou have contributed equally to the preparation of this paper.

Funding

This work was supported by the Open Program of Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province (No: 2021LZXNYD-J11).

Author information

Authors and Affiliations

  1. Department of Nephrology, The Affiliated Hospital of Southwest Medical University, The 25th Taiping Street, Luzhou, 646000, Sichuan Province, China

    Jingyi Chen, Xiangqiong Wen, Xin Xie & Santao Ou

  2. Sichuan Clinical Research Center for Nephropathy, Luzhou, Sichuan Province, China

    Jingyi Chen, Xiangqiong Wen, Xin Xie & Santao Ou

  3. Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China

    Liang Cai

  4. Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, Sichuan, China

    Liang Cai

  5. Academician (Expert) Workstation of Sichuan Province, Luzhou, Sichuan, China

    Liang Cai

Authors
  1. Jingyi Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Liang Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiangqiong Wen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xin Xie
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Santao Ou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Santao Ou.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethics approval

The study was approved by the Ethics Committee of the Affiliated Hospital of Southwest Medical University of China.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chen, J., Cai, L., Wen, X. et al. Paricalcitol in the treatment of MHD with secondary hyperparathyroidism and bone pain. Int Urol Nephrol 55, 1385–1388 (2023). https://doi.org/10.1007/s11255-022-03421-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-022-03421-z

Search

Navigation